We are live on
!
Find out more
GT
Glenmede Trust Portfolio holdings
AUM
$20.4B
This Fund
S&P 500
This Quarter
Est. Return
+23.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16.4B
AUM Growth
-$5.58B
(-25%)
Cap. Flow
-$3.87B
Cap. Flow
% of AUM
-23.65%
Top 10 Holdings %
Top 10 Hldgs %
18.07%
Holding
3,458
New
283
Increased
974
Reduced
1,077
Closed
907
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$97.1M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
+$76.6M |
| 3 |
Lowe's Companies
LOW
|
+$75.4M |
| 4 |
Monster Beverage
MNST
|
+$64.6M |
| 5 |
FISV
Fiserv Inc
FISV
|
+$63.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$114M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$109M |
| 3 |
Trane Technologies
TT
|
+$106M |
| 4 |
Microsoft
MSFT
|
+$104M |
| 5 |
Mastercard
MA
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.03% |
| 2 | Healthcare | 13.89% |
| 3 | Financials | 11.27% |
| 4 | Consumer Discretionary | 8.92% |
| 5 | Industrials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
HSBC
HSBC
$352B
| $204K | ﹤0.01% |
8,820
-2,644
| -23% | -$65.7K |
|
1002
Quanterix
QTRX
$159M
| $204K | ﹤0.01% |
+7,473
| New | +$189K |
|
1003
RLI Corp
RLI
$6.02B
| $204K | ﹤0.01% |
4,980
+220
| +5% | +$8.68K |
|
|
KYNB
1004
Kyntra Bio
KYNB
$27.4M
| $203K | ﹤0.01% |
+201
| New | +$187K |
|
1005
Five Below
FIVE
$11.6B
| $203K | ﹤0.01% |
1,906
+1,228
| +181% | +$115K |
|
1006
FIVE9
FIVN
$2.08B
| $203K | ﹤0.01% |
1,838
-6,471
| -78% | -$630K |
|
1007
Iovance Biotherapeutics
IOVA
$2.04B
| $203K | ﹤0.01% |
7,430
+400
| +6% | +$13.2K |
|
1008
iShares Europe ETF
IEV
$1.64B
| $202K | ﹤0.01% |
5,000
| – | – |
|
|
MASI
1009
DELISTED
Masimo
MASI
| $202K | ﹤0.01% |
+888
| New | +$195K |
|
|
CHL
1010
DELISTED
China Mobile Limited
CHL
| $202K | ﹤0.01% |
6,026
+682
| +13% | +$25.2K |
|
1011
Bank of America Series L
BAC.PRL
$3.93B
| $201K | ﹤0.01% |
150
| – | – |
|
1012
US Foods
USFD
$22.5B
| $200K | ﹤0.01% |
10,165
-10,026
| -50% | -$192K |
|
1013
ITT
ITT
$17.1B
| $199K | ﹤0.01% |
3,400
+249
| +8% | +$13.2K |
|
|
MNTA
1014
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $199K | ﹤0.01% |
6,010
+5,149
| +598% | +$164K |
|
1015
Schwab US Dividend Equity ETF
SCHD
$104B
| $198K | ﹤0.01% |
11,538
+8,517
| +282% | +$144K |
|
1016
Acadia Pharmaceuticals
ACAD
$4.51B
| $195K | ﹤0.01% |
4,028
-5,753
| -59% | -$276K |
|
1017
CBIZ
CBZ
$2.95B
| $195K | ﹤0.01% |
8,166
+2,836
| +53% | +$64.4K |
|
1018
Cullen/Frost Bankers
CFR
$10.5B
| $194K | ﹤0.01% |
2,616
-3,020
| -54% | -$210K |
|
|
HRC
1019
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $194K | ﹤0.01% |
1,781
-1,010
| -36% | -$106K |
|
|
ANSS
1020
DELISTED
Ansys
ANSS
| $193K | ﹤0.01% |
662
-18
| -3% | -$4.79K |
|
1021
Scotiabank
BNS
$105B
| $192K | ﹤0.01% |
4,680
-456
| -9% | -$18.2K |
|
1022
Revolve Group
RVLV
$1.85B
| $192K | ﹤0.01% |
+12,971
| New | +$170K |
|
1023
Insight Enterprises
NSIT
$3.85B
| $191K | ﹤0.01% |
3,908
+3,342
| +590% | +$165K |
|
1024
Pinnacle Financial Partners Inc
PNFP
$15.8B
| $191K | ﹤0.01% |
4,573
+191
| +4% | +$7.58K |
|
|
MYOK
1025
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $191K | ﹤0.01% |
+1,987
| New | +$166K |
|
Similar funds
EWA
MIC
P
OSAM
CB
EIM
SC
Glenmede Trust's Q2 2020 Portfolio in Review
As of Q2 2020, Glenmede Trust held 3,458 positions worth $16.4B, down 25% from $21.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Glenmede Trust withdrew a net $3.87B in Q2 2020, closing 907 positions and reducing 1,077 holdings. Its most notable exit was Raytheon Company, an estimated $66.5M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Glenmede Trust opened a new position in Carrier Global worth $21.3M.
- Glenmede Trust's largest Q2 2020 buy was Carrier Global: 960,042 shares worth $21.3M.
- Glenmede Trust added most to State Street SPDR S&P 500 ETF Trust in Q2 2020, an estimated $97.1M increase.
- Glenmede Trust's biggest Q2 2020 reduction was Accenture, cutting an estimated $114M.
- Glenmede Trust fully exited Raytheon Company in Q2 2020, selling an estimated $66.5M.
- Glenmede Trust's ten largest holdings make up 18% of its $16.4B portfolio in Q2 2020.
- Glenmede Trust opened 283 new positions and closed 907 in Q2 2020.
- Glenmede Trust's portfolio value fell 25% quarter-over-quarter to $16.4B.
Based on Glenmede Trust's 13F filing for Q2 2020, filed 14 Aug 2020.